DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Research summary · not a treatment plan
BPC-157 + TB-500
BPC-157 + TB-500 Recovery Stack
- US pathway
- Awaiting FDA
- Studied for
- recovery
- Route
- subcutaneous
01
Dosing as studied
BPC-157 250 mcg daily + TB-500 2.0 mg 2x/week near injury site.
02
Cycle length
6–8 weeks
03
Contraindications
Active cancer is an absolute contraindication.
04
Notes
Most popular recovery combination in clinical practice.
05
Regulatory status
The Peptide Association does not endorse or recommend any specific treatment protocol. This page summarizes how BPC-157 + TB-500 has been used and studied. Whether it is right for you, and at what dose, is a decision for a licensed clinician.
BPC-157 and TB-500 are not FDA-approved, and as of October 2026 FDA has not finalized whether pharmacies may compound them.
This protocol is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide therapy.